9/8/2023 0 Comments Free mixed in key downloadManagement of patients with intermediate stage hepatocellular carcinoma. Optimizing curative management of hepatocellular carcinoma. Recent advances in the surgical management of hepatocellular carcinoma. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Analysis on liver cancer mortality and cause eliminated life expectancy in key areas of 4 provinces, China, 2008–2018. Analysis on incidence trend of liver cancer in China, 2005–2016. Epidemiological characteristics of primary liver cancer in mainland china from 2003 to 2020: a representative multicenter study. Evaluation of the health economic impact of initial diagnostic modality selection in patients suspected of having HCC in China and the USA. TACE combined with targeted treatment for intermediate to advanced unresectable HCC was effective, with good tumor responsiveness, high surgical conversion rate, and safe and controllable adverse reactions during treatment. No patient experienced catheter retention-related complications during treatment, and there were no intolerable adverse effects. Multifactorial regression analysis identified tumor vascular invasion as an independent prognostic factor affecting HCC. Compared with TACE treatment alone, the objective response rate (ORR) was significantly higher in the TACE combined with targeted treatment group (50.0% vs 36.4%), with a higher success rate of surgical conversion (33.3% vs 18.2%) and a significantly longer progression-free survival (PFS) (20.5 ± 2.9 months vs 11.6 ± 2.9 months). The basal indexes of patients in the two groups were compared, and the response during treatment was observed regular follow-up was performed to assess the efficacy of tumor treatment. Prospective analysis of 23 patients with intermediate or advanced primary HCC treated at the Department of Hepatic Surgery, The First Affiliated Hospital of the University of Science and Technology of China from July 2019, including 11 cases treated with TACE alone and 12 cases treated with TACE combined with targeted therapy. To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune and targeted therapy in unresectable hepatocellular carcinoma (HCC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |